Updates are available Correction dated 2022-02-18
Click to view Correction: https://doi.org/10.1038/s41571-022-00611-7
-
Authors
Petroni, Giulia
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Santambrogio, Laura
Formenti, Silvia C. https://orcid.org/0000-0002-8227-8924
Galluzzi, Lorenzo https://orcid.org/0000-0003-2257-8500
- License Information
-
More Information
Article History
Accepted: 28 October 2021
First Online: 24 November 2021
Change Date: 18 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41571-022-00611-7
Competing interests
: L.S. has received research funding from Puretech. L.C.C. has acted as a consultant and/or advisor to Agios Pharmaceuticals, Faeth Therapeutics, Larkspur Therapeutics and Volastra Therapeutics, has received research funding from Petra Pharmaceuticals and is a co-founder of, and holds equity in, Agios Pharmaceuticals, Faeth Therapeutics, Larkspur Therapeutics and Volastra Therapeutics. S.C.F. has acted as a consultant and/or advisor to AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Elekta, EMD Serono, GlaxoSmithKline, Janssen, MedImmune, Merck US, Regeneron, Varian and ViewRay, and has received research funding from Bristol Myers Squibb, Eli-Lilly, Merck, Regeneron and Varian; and other support from Pfizer. L.G. has acted as a consultant and/or advisor to AstraZeneca, Boehringer Ingelheim, Inzen, The Longevity Labs, the Luke Heller TECPR2 Foundation, OmniSEQ and Onxeo, and has received research funding from Lytix, and Phosplatin. G.P. declares no competing interests.
